- 1 Title:
- 2 Vitamin D levels and COVID-19 severe pneumonia: a prospective case-control study
- 3
- 4
- 5 Running title:
- 6 Vitamin D and COVID-19 severe pneumonia
- 7
- 8
- 9

```
10 Authors:
```

- 11 Fortunato José Cardoso, Department of Gastroenterology, Instituto de Medicina
- 12 Integral Prof. Fernando Figueira (IMIP)
- 13 Carla Adriane Leal de Araújo, Department of Pediatrics, Instituto de Medicina Integral
- 14 Prof. Fernando Figueira (IMIP)
- 15 José Roberto da Silva Junior, Department of Postgraduate, Instituto de Medicina
- 16 Integral Prof. Fernando Figueira (IMIP)
- 17 Angélica Guimarães, Department of Pediatrics, Hospital Dom Malan (HDM)
- 18 Michelle Viana Taveiro, Department of Pediatrics, Universidade do Vale do São
- 19 Francisco (UNIVASF)
- 20 José Natal Figueiroa, Department of Biostatistic, Instituto de Medicina Integral Prof.
- 21 Fernando Figueira (IMIP)
- 22 João Guilherme Bezerra Alves, Department of Pediatrics, Instituto de Medicina Integral
- 23 Prof. Fernando Figueira (IMIP)
- 24

Corresponding author:

- 26 João Guilherme Bezerra Alves
- 27 Department of Pediatrics, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
- 28 Rua dos Coelhos, 300, Boa Vista, Recife, Pernambuco Brazil
- 29 ZIP: 50070-550
- 30 Phone: +55 (81) 99974-6351
- 31 e-mail: joaoguilherme@imip.org.br

4		

47	
48	
49	
50	Abstract
51	Introduction: The hypothesis that a low vitamin D levels is associated with a higher
52	risk for severe COVID-19 has not been completely proven, especially with severe
53	pneumonia. Objective: The goal of this study was to confirm the link between vitamin
54	D levels and COVID-19 severe pneumonia. Methods: This prospective case-control
55	study involved 307 patients who developed severe SARS-CoV-2 pneumonia and were
56	hospitalized in an intensive care unit. Age- and sex-matched controls (307) were
57	selected from the same population; 307 patients with mild to moderate forms of
58	COVID-19 who were not hospitalized. Vitamin D levels were assessed during the
59	duration of the disease. Results: The mean vitamin D level was lower in the severe
60	COVID-19 pneumonia group as compared to the control group; 26.8 \pm 7.6 ng/mL vs
61	28.6 \pm 7.4 ng/mL, p<0.002. There were more patients with a sufficient level of vitamin D
62	in the control group as compared to the control group; 127 (20.6%) vs 89 (14.5%),
63	p<0.001. Multivariable analysis showed that a deficient vitamin D level was associated

64 with a higher risk for severe COVID-19 pneumonia (OR=3.0; 95% CI: 1.79, 5.10CI),

65 p<0.001. Conclusion: A sufficient vitamin D level is linked to a lower risk of COVID-19 66 severe pneumonia.

67 Keywords: COVID-19; SARS-CoV-2; severe pneumonia; vitamin D; severe COVID=19

68

69

4

71

72 Introduction

73	The COVID-19 pandemic has become a global threat, not only because of its
74	impact on health but also because of the great economic burden it has placed on the
75	lives of the affected populations [1]. Although in the last few months the pandemic has
76	decreased worldwide, a new wave of COVID has arisen in the last few months in some
77	countries with SARS-CoV-2 Omicron subvariants, especially BQ.1, BQ.1, and XBB [2,
78	3].

79 Infection with SARS-CoV-2 is silent or a benign upper respiratory disease in 80 80% of cases and causes pneumonia in 20% of cases [4, 5]. Approximately half of 81 these patients develop hypoxemic pneumonia, requiring hospitalization and, 82 sometimes, UTI admission and mechanical ventilation. Pneumonia represents the 83 typical presentation of COVID-19 and is the main mortality cause [6, 7]. SARS-CoV-2 84 pneumonia can lead to acute hypoxic respiratory failure, multiorgan failure, and death 85 [8, 9]. SARS-CoV-2 leads to diffuse alveolar damage and micro- and macrothrombi in 86 pulmonary arterial vessels, resulting in profound oxygen desaturation and respiratory 87 distress [10].

88 Due to the presence of the vitamin D receptor in various types of cells and 89 tissues, vitamin D has many biologic activities in various organ systems and acts as an 90 immunomodulatory factor in the prevention of respiratory infections [11, 12]. Some 91 studies have reported that vitamin D may be involved both in the SARSCoV-2 92 replication process and in the binding of the virus to the host [13, 14, 15]. COVID-19 93 has been more commonly reported in regions with populations with low vitamin D, 94 including patients with severe COVID-19 disease [16, 17, 18, 19]. However, these 95 studies have demonstrated conflicting results. A recent meta-analysis showed that the

5

96	evidence of vitamin D protection against hospitalization, ICU admission, and pulmonary
97	involvement is currently inconsistent and insufficient [20]. Another recent systematic
98	review concluded that deficient vitamin D levels were not associated with an increased
99	mortality rate in patients with COVID-19 when the analysis included studies with
100	adjustments for confounders [21]. In conclusion, the relationship between COVID-19
101	and vitamin D has biological plausibility, but the studies available currently are not
102	conclusive [22].

103 The hypothesis that a low vitamin D levels is associated with a higher risk for

severe COVID-19 has not been completely proven, especially with severe pneumonia.

105 Based on all this, this case-control study verified the association between vitamin D

106 level and the risk of severe COVID-19 pneumonia.

107 Subjects and Methods

108 This prospective matched case-control study was performed in Recife,

109 Northeast, Brazil. Patients were enrolled at the Instituto de Medicina Integral Prof.

110 Fernando Figueira (IMIP), and Hospital Dom Malan (HDM). Case and control patients

111 were selected between April 2020 and February 2022 from patients treated with

112 COVID-19 at IMIP and HDM.

113 This observational study followed the ethical standards of the 1964 Declaration

of Helsinki and its later amendments. This study was previously approved by the

115 Research Ethical Committee of IMIP (CAAE: 40857920.0.0000.5201). Written informed

116 consent was previously obtained from each participant.

117 Patients hospitalized in an intensive care unit with COVID-19 severe pneumonia

and over the age of 18 who were considered case patients. COVID-19 severe

119 pneumonia was considered according to the following definition: shortness of breath,

low SpO2, and pulmonary alteration on a CT image. A positive reverse transcription

6

polymerase chain reaction (RT-PCR) test of pharyngeal and nasal swab samples was
used to confirm the SARS-Cov-2 infection. For every case patient, a patient with mild
or moderate COVID-19 was selected as a control, always matched by age (±5 years)
and gender. Controls were selected from the same hospitals.

125 The vitamin D level was assessed using a chemiluminescence-based

immunoassay analyzer. Pacients were classified according to vitamin D values as

127 deficient (<20 ng/mL), insufficient (\geq 20 and \leq 30 ng/mL), and sufficient (>30 ng/mL).

128 The sample size was determined based on the following information: (1) 129 significance level of 0.05; (2) power=0.8; (3) proportion of those who were exposed to

the protection factor (sufficient vitamin D level) versus those who were not exposed

131 (deficient or insufficient vitamin D level); a difference of 12% in the outcome (COVID-19

132 severe pneumonia); the value of the minimum odds ratio to be detected (0.2); and a

133 case-to-control ratio of one case to one control. A total of 614 patients were calculated;

134 Categorical variables are presented as frequencies and percentages, while continuous variables are presented as means and standard deviations (SDs). The 135 136 demographic and clinical variables of the case and control patients were compared 137 using the chi-square test or Student's t-test. Multivariable logistic regression was used 138 to assess the independent association between vitamin D levels and SARS-CoV-2 139 severe pneumonia after adjustment for categorical and continuous variables. Results 140 were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical analyses were performed using STATA version 12.1 (USA). A p value of 0.05 was 141 considered statistically significant. 142

143

144 Results

7

145	A total of 314 patients were studied; 307 case patients hospitalized with COVID-
146	19 severe pneumonia, and 307 matched controls for age and gender, all PCR positive
147	for SARS-CoV-2. There was no difference in the mean age (49.2 \pm 13.0 years vs.
148	48.7 ± 11.0 years; p = 0.631) or gender (307 males vs. 307 females), respectively, in
149	the cases or control patients. Obesity, overweight, systemic hypertension, type 2
150	diabetes, smoking, and drinking habits showed no differences between cases and
151	controls (Table 1).
152	The mean vitamin D level was lower in case patients as compared to control

153 patients, respectively: 26.8 ± 7.6 ng/mL vs. 28.6 ± 7.4 ng/mL, p < 0.002. Vitamin D

deficiency and insufficiency were more common in the case group (p < 0.001) (Table

155 2). Multivariable analysis showed that a low vitamin D level was independently

156 associated with a higher risk for SARS-CoV-2 severe pneumonia, 95% CI (1.38 –

157 3.01), p < 0.001 (Table 3).

158

159 Discussion

This prospective case-control study showed that a sufficient vitamin D level was 160 161 associated with a lower risk of SARS-CoV-19 severe pneumonia. Inversely, a deficient or insufficient vitamin D level increased the risk of SARS-CoV-2-related severe 162 163 pneumonia. Our findings are in agreement with other observational studies that have 164 approached the severity of illness in COVID-19. However, unlike other studies, our severity criterion used in this study was that of severe pneumonia, i.e., admission to an 165 166 intensive care unit and complaints of shortness of breath, low SpO2, and pulmonary alteration on a CT image. Nimavat et al. found no statistical difference between the 167 mean vitamin D level among 156 cases and 204 controls (p = 0.757), but vitamin D 168 169 deficiency was observed in 37.1 % of severe pneumonia cases compared to 20 % and

8

170 10.1 % among mild and moderate cases, respectively [23]. However, only 23 patients 171 were studied with COVID-19 severe pneumonia. Ye et al. also reported a higher 172 percentage of vitamin D deficiency among patients with severe disease as compared to mild/moderate disease, but they studied only 10 patients with COVID-19 severe 173 pneumonia [24]. Israel et al. in a large retrospective case-control study based on an 174 Israeli database, showed a significant association between vitamin D deficiency and 175 176 the risks of SARS-CoV-2 severe disease [25]. However, they measured vitamin D levels a long time before hospitalization. These findings, however, are not unanimous. 177 178 Novakovic et al. studied 685 patients hospitalized with COVID-19 and did not find an

association between vitamin D level and 30-day mortality [26].

179

180 Some systematic reviews have also examined the association between vitamin 181 D levels and COVID-19 severity. These reviews tend to converge on an inverse 182 association between vitamin D levels and COVID-19 severity. However, the authors 183 emphasize the need for further studies because of the low or moderate quality of the 184 studies. Pereira et al. [27] concluded that vitamin D deficiency was not associated with 185 a higher chance of infection by COVID-19 (OR = 1.35; 95% CI = 0.80-1.88), but that severe cases of COVID-19 present 64% (OR = 1.64; 95% CI = 1.30-2.09) more vitamin 186 D deficiency compared with mild cases. Ebrahimzadeh et al. [28] found a significant 187 188 direct association between vitamin D deficiency and an elevated risk of COVID-19 in-189 hospital mortality. Kazemi et al. [29] concluded that lower vitamin D levels correlated with disease severity and a poor prognosis, but most of the studies were observational 190 191 and of moderate quality. On the other hand, Al Kiyumi et al. [30] concluded that the 192 evidence of vitamin D deficiency and COVID-19 hospitalization, ICU admission, and 193 pulmonary involvement, was inconsistent and insuficient.

194 It has been hypothesized that there are some potential mechanisms to explain
195 the observed association between vitamin D levels and SARS-CoV-2 infection severity.

9

196 Vitamin D competes to maintain cell junctions and has protective effects against 197 thrombosis, endothelial dysfunction, and thrombosis. SARS-CoV-2 disrupts cell 198 junction integrity [31]. Vitamin D also enhances cellular innate immunity and interferes 199 with viral replication through the induction of antimicrobial peptides [32]. Vitamin D still 200 promotes the production of antimicrobial and antiviral proteins (β -defensin 2 and 201 cathelicidin), both of which inhibit the replication of SARS-CoV-2 and stimulate the 202 clearance of virus from cells by autophagy [32]. Besides, it has been suggested that 203 vitamin D stimulates ACE2 receptors, which can bind to SARS-CoV-2 and prevent it 204 from attaching to ACE2 receptors and entering the cells [33]. Finally, vitamin D has 205 anti-inflammatory effects, including inhibition of TNF- α (tumor necrosis factor- α) and IL-206 6 which can help to avoid a cytokine storm and hyper-inflammatory state caused by 207 SARS-CoV-2 and associated with high mortality [33].

208 Our research has strengths and limitations. This case control study had 209 prospective recruitment and contemporaneous control subjects, and only patients with 210 COVID-19 severe pneumonia with intensive care admission were included. We did not 211 identify observational studies exploring this association in tropical regions where 212 people are exposed to sunlight almost all days of the year. Besides, our study included 213 two health reference centers in Pernambuco State, Brazil, and had the sample size 214 calculated. However, our findings must be interpreted with caution because of certain 215 limitations. First, we could not control the vaccine response in case studies or control 216 patients because, until the middle of the study, vaccines for COVID were not yet being 217 applied in Brazil. Second, we did not include cases of death. Our study design included 218 patients in the intensive care unit, and they had to be able to respond to a 219 guestionnaire at the time of discharge from the intensive care unit, which made it 220 impossible to study patients who died.

221 This finding emphasizes the protective effects of a sufficient vitamin D level 222 against the risks of COVID-19 severe pneumonia. This result has critical implications

10

223	for public health,	especially	considering that,	until now,	COVID-19 had no	specific
-----	--------------------	------------	-------------------	------------	-----------------	----------

treatment. Thus, it is mandatory to encourage the general population to keep their

- 225 vitamin D levels sufficient in their everyday routine to reduce the risk of COVID-19
- severe pneumonia, the main cause of COVID-19 mortality.

227 Conclusion

- 228 Previous studies have shown that vitamin D levels are associated with the
- 229 severity of illness and mortality in COVID-19 patients. This study adds that a sufficient
- 230 vitamin D level offers protection against COVID-19 severe pneumonia hospitalization
- and admission to the intensive care unit. Further clinical trial studies are needed to
- 232 confirm these findings of the beneficial effect of vitamin D on COVID-19 severe
- 233 pneumonia.
- 234
- 235

236 Ethics approval and consent to participate

This study followed the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained previously from each participant. This study was previously approved by the Research Ethical Committee of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP); CAAE (Certificate of Presentation of Ethical Appreciation): 40857920.0.0000.5201.

242

243 Availability of data and materials

- 244 Data are available from the authors upon reasonable request and with permission
- from the Instituto de Medicina Integral Prof. Frnando Figueira (IMIP) www.imip.org.br

246 Competing interests

247 None declared

248

- 249 Funding
- 250 CNPq (Brazilian National Council for Scientific and Technological
- 251 Development), grant number 401907/2020-1.

252

253 Authors' contributions

- JGBA and FJC conceived the study. FJC, CAA, JRSJ, and MRT participated in
- the data collection. JGBA and JNF analyzed the data. JGBA and FJC wrote the main
- 256 manuscript text. All authors reviewed the manuscript.

257

258 Acknowledgments

- 259 The authors would like to thank to the CNPq (Brazilian National Council for
- 260 Scientific and Technological Development), who financed this study, grant number
- 261 401907/2020-1.

262

- 264
- 265 References

- 1 Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19 outbreak:
- 267 Impact on global economy. Front Public Health. 2023;10:1009393. doi:
- 268 10.3389/fpubh.2022.1009393.
- 269 2 Mohsin M, Mahmud S. Omicron SARS-CoV-2 variant of concern: A review on its
- transmissibility, immune evasion, reinfection, and severity. Medicine (Baltimore).
- 271 2022;101(19):e29165. doi: 10.1097/MD.000000000029165.
- 272 3 Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y. Alarming antibody evasion
- properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-
- 274 286.e8. doi: 10.1016/j.cell.2022.12.018.
- 4 Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi L, Juden-Kelly C, Moghadas SM et al.
- 276 Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc
- 277 Natl Acad Sci U S A 2021; 118(34).
- 278 5 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A
- 279 Narrative Review. Ann Intern Med 2020;173(5):362–367
- 280 6 Budinger GRS, Misharin AV, Ridge KM, Singer BD, Wunderink RG. Distinctive
- features of severe SARS-CoV-2 pneumonia. J Clin Invest. 2021;131(14):e149412. doi:
- 282 10.1172/JCI149412.
- 283 7 Ketcham SW, Bolig TC, Molling DJ, Sjoding MW, Flanders SA, Prescott HC.
- 284 Causes and Circumstances of Death among Patients Hospitalized with COVID-19: A
- 285 Retrospective Cohort Study. Ann Am Thorac Soc. 2021;18(6):1076-1079. doi:
- 286 10.1513/AnnalsATS.202011-1381RL.
- 287 8 Santus P, Radovanovic D, Saderi L, Marino P, Cogliati C, Filippis G et al. Severity
- of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a
- prospective observational multicentre study. BMJ Open. 2020;10(10)
- 290 doi: 10.1136/bmjopen-2020-043651.

- 291 9 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 292 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
- 293 Review. JAMA. 2020;324(8):782-793. doi: 10.1001/jama.2020.12839.
- 10 Carsana L, Sonzogni A, Nasr A, Ross RS, Pellegrinelli A, Zerbi P et al. Pulmonary
- 295 post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre
- 296 descriptive study. Lancet Infect Dis. 2020;20(10):1135–1140. doi: 10.1016/S1473-
- 297 3099(20)30434-5.
- 298 11 Holick MF. Medical progress: vitamin D deficiency. N Engl J
- 299 *Med.* 2007;357(3):266–281. doi: 10.1056/NEJMra070553.
- 300 12 Rossetti M, Martucci G, Starchl C, Amrein K. Micronutrients in Sepsis and COVID-
- 301 19: a narrative review on what we have learned and what we want to know in future
- 302 trials. *Medicina*. 2021;57(5):419. doi: 10.3390/medicina57050419.
- 13 Qayyum S, Mohammad T, Slominski RM, Hassan MI, Tuckey RC, Raman C et al.
- 304 Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication
- machinery enzymes. Am J Physiol Endocrinol Metab. 20211;321(2):E246-E251. doi:
- 306 10.1152/ajpendo.00174.2021.
- 307 14 Mansouri A, Kowsar R, Zakariazadeh M, Hakimi H, Miyamoto A. The impact of
- 308 calcitriol and estradiol on the SARS-CoV-2 biological activity: a molecular modeling
- 309 approach. Sci Rep. 2022 ;12(1):717. doi: 10.1038/s41598-022-04778-y.
- 310 15 Shalayel MH, Al-Mazaideh GM, Aladaileh SH, Al-Swailmi FK, Al-Thiabat MG.
- 311 Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding
- site of SARS-CoV-2 endoribonuclease Nsp15. Pak J Pharm Sci. 2020;33(5):2179-
- 313 2186.
- 16 Rhodes JM, Subramanian S, Laird E, Kenny RA. Editorial: low population mortality
- from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a

14

factor determining severity. Aliment Pharmacol Ther. 2020;51(12):1434–1437.

- 317 doi: 10.1111/apt.15777.
- 17 Merzon E, Tworowski D, Gorohovski A, Vinker S, Cohen AG, Green I et al. Low
- 319 plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection:
- an Israeli population-based study. FEBS J. 2020;13:644.
- 18 Panagiotou G, Tee SA, Ihsan Y, et al. Low serum 25-hydroxyvitamin D (25[OH]D)
- 322 levels in patients hospitalised with COVID-19 are associated with greater disease
- 323 severity. Clin Endocrinol. 2020 doi: 10.1111/cen.14276.
- 19 D'Avolio A, Avataneo V, Manca A, Lusato J, Nicolo A, Lucchini R et al. 25-
- 325 hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-
- 326 CoV-2. Nutrients. 2020;12:1359. doi: 10.3390/nu12051359.
- 327 20 Kazemi A, Mohammadi V, Aghababaee SK, et al. Association of Vitamin D Status
- 328 with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-

analysis. Adv Nutr. 2021;12(5):1636-1658. doi: 10.1093/advances/nmab012.

- 330 21 Bignardi PR, de Andrade Castello P, de Matos Aquino B, et al. Is the vitamin D
- 331 status of patients with COVID-19 associated with reduced mortality? A systematic
- review and meta-analysis. Arch Endocrinol Metab. 2023;67(2):276-288. doi:
- 333 10.20945/2359-3997000000588.
- 334 22 Contreras-Bolívar V, García-Fontana B, García-Fontana C, et al. Vitamin D and
- 335 COVID-19: where are we now? Postgrad Med. 2023;135(3):195-207. doi:
- 336 10.1080/00325481.2021.2017647.
- 337 23 Nimavat N, Singh S, Singh P, et al. Vitamin D deficiency and COVID-19: A case-
- control study at a tertiary care hospital in India. Ann Med Surg (Lond). 2021; 68:
- 339 102661. doi: 10.1016/j.amsu.2021.102661

- 340 24 Ye K, Tang F, Liao X, Deng M, Huang G, Qin Z et al. Does serum vitamin D level
- affect COVID-19 infection and its severity? A case-control study. J. Am. Coll. Nutr.
- 342 2020 doi: 10.1080/07315724.2020.1826005.
- 343 25 Israel A, Cicurel A, Feldhamer I, Stern F, Dror X, Giveon SM et al.
- 344 Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection
- and COVID-19 severity: a retrospective case-control study.Intern Emerg Med. 2022
- 346 ;17(4):1053-1063. doi: 10.1007/s11739-021-02902-w.
- 347 26 Novakovic V, Benfield T, Jørgensen HL, Mitchell NH. Vitamin D as a
- prognostic biomarker in COVID-19: single-center study and meta-analyses.
- 349 Scand J Clin Lab Invest. 2023;83(3):173-182. doi:
- 350 10.1080/00365513.2023.2191333.
- 351 27 Pereira M, Damascena AD, Azevedo LMG, et al. Vitamin D deficiency aggravates
- 352 COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr.
- 353 2022;62(5):1308-1316. doi: 10.1080/10408398.2020.1841090.
- 28 Ebrahimzadeh A, Mohseni S, Narimani B, Ebrahim ZA, Kazemi S, Keshavarz F et
- al. Association between vitamin D status and risk of covid-19 in-hospital mortality:
- A systematic review and meta-analysis of observational studies. .Crit Rev Food Sci
- 357 Nutr. 2021:1-11. doi: 10.1080/10408398.2021.2012419.
- 358 29 Kazemi A, Mohammadi V, Aghababaee SK, et al. Association of Vitamin D Status
- 359 with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-
- analysis. Adv Nutr. 2021;12(5):1636-1658. doi: 10.1093/advances/nmab012.
- 361 30 Al Kiyumi MH, Kalra S, Davies JS, Khalan A. The Impact of Vitamin D Deficiency
- on the Severity of Symptoms and Mortality Rate among Adult Patients with Covid-19:

16

- A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2021;25(4):261-
- 364 282. doi: 10.4103/ijem.ijem_115_21.
- 365 31 Kumar R, Rathi H, Haq A, Wimalawansa S, Sharma A. Putative roles
- of vitamin D in modulating immune response and immunopathology associated with
- 367 COVID-19. Virus Res. 2021;292:198235. doi: 10.1016/j.virusres.2020.198235.
- 368 32 Gilani SJ, Bin-Jumah MN, Nadeem MS, Kazmi I. Vitamin D attenuates COVID-19
- 369 complications via modulation of proinflammatory cytokines, antiviral proteins, and
- autophagy. Expert Rev Anti Infect Ther. 2022;20(2):231-241. doi:
- 371 10.1080/14787210.2021.1941871.
- 372 33 Contreras-Bolívar V, García-Fontana B, García-Fontana C, Munoz-Torres M.
- Vitamin D and COVID-19: where are we now? Postgrad Med. 2023;135(3):195-207.
- doi: 10.1080/00325481.2021.2017647.
- 375
- 376
- 377
- 378
- 379
- 380

381

- 382
- 383
- 384
- 385

386

388				
389				
390				
391				
392				

393

19

395 Table 1. Some characteristics between case and control groups

396

397	Variable	Case (307)	Control (307)	
	Obesity	41 (13.3%)	27 (8.7%)	0.071
	Overweight	179 (58.3%)	158 (51.5%)	0.089
	Smoking	23 (7.4%)	19 (6.1%)	0.523
	Drinking	146 (47.6%)	142 (46.2%)	0.746
	Diabetes Type 2	44 (14.3%)	38 (12.3%)	0.477
	Hypertension	110 (35.8%)	117 (38.1%)	0.558

398

20

400 **Table 2**. Univariable analysis of some variables between patients with (Cases) and

401 without (Controls) severe SARS-CoV-19 pneumonia

Sample	Case	Control		
	(N = 307)	(N = 307)		
N	N (%)	N (%)	OR (IC95%)	Valor p
				0.480
82	44 (14.3)	38 (12.4)	1.2 (0.74 - 1.88)	
532	263 (85.7)	269 (87.6)	1.0	
				0.538
42	23 (7.5)	19 (6.2)	1.2 (0.66 - 2.22)	
572	284 (92.5)	288 (93.8)	1.0	
				0.742
288	146 (47.6)	142 (46.2)	1.1 (0.76 - 1.46)	
326	161 (52.4)	165 (53.8)	1.0	
				0.566
227	109 (34.5)	118 (38.4)	0. 9 (0.66 - 1.26)	
387	198 (64.5)	189 (61.6)	1.0	
				0.0971
216	80 (26.1)	136 (44.3)	1.0	
337	179 (58.3)	158 (51.5)	1.9 (1.33 – 2.68)	
68	41 (13.3)	27 (8.7)	3.4 (3.14 – 8.90)	
				< 0.001
294	162 (55,1)	132 (44,9)	2.2 (1.51 – 3.45)	< 0.001
90	62 (68,9)	28 (31,1)	3.4 (2.08 – 5.75)	< 0.001
230	83 (36,1)	147 (63,9)	1.0	
	Sample N 82 532 42 572 288 326 227 387 216 337 68 294 90 230	SampleCase $(N = 307)$ NN (%)8244 (14.3)532263 (85.7)4223 (7.5)572284 (92.5)288146 (47.6)326161 (52.4)227109 (34.5)387198 (64.5)21680 (26.1)337179 (58.3)6841 (13.3)294162 (55,1)9062 (68,9)23083 (36,1)	SampleCaseControl $(N = 307)$ $(N = 307)$ NN (%)N (%)8244 (14.3)38 (12.4)532263 (85.7)269 (87.6)4223 (7.5)19 (6.2)572284 (92.5)288 (93.8)288146 (47.6)142 (46.2)326161 (52.4)165 (53.8)227109 (34.5)118 (38.4)387198 (64.5)189 (61.6)21680 (26.1)136 (44.3)337179 (58.3)158 (51.5)6841 (13.3)27 (8.7)294162 (55.1)132 (44.9)9062 (68.9)28 (31.1)23083 (36.1)147 (63.9)	SampleCaseControl $(N = 307)$ $(N = 307)$ N $N(\%)$ $N(\%)$ $OR (IC95\%)$ 8244 (14.3) $38 (12.4)$ $1.2 (0.74 - 1.88)$ 532263 (85.7)269 (87.6) 1.0 4223 (7.5)19 (6.2) $1.2 (0.66 - 2.22)$ 572284 (92.5)288 (93.8) 1.0 288146 (47.6)142 (46.2) $1.1 (0.76 - 1.46)$ 326161 (52.4)165 (53.8) 1.0 227109 (34.5)118 (38.4) $0.9 (0.66 - 1.26)$ 387198 (64.5)189 (61.6) 1.0 21680 (26.1)136 (44.3) 1.0 337179 (58.3)158 (51.5) $1.9 (1.33 - 2.68)$ 6841 (13.3)27 (8.7) $3.4 (3.14 - 8.90)$ 294162 (55.1)132 (44.9) $2.2 (1.51 - 3.45)$ 9062 (68.9)28 (31.1) $3.4 (2.08 - 5.75)$ 23083 (36.1)147 (63.9) 1.0

402

Table 3. Multivariable analysis of some variables between patients with (Cases) and

405 without (Controls) severe SARS-CoV-19 pneumonia

	Multivariable Model			
Variable	OR (95% CI)	p value		
Nutritional Status				
Normal	1.0	0.093		
Overweight	1.8 (1.26 – 2.61)			
Obesity	3.3 (2.84 – 8.34)			
Vitamin D Level		<0.001		
Insuficient	2.0 (1.38 – 3.01)			
Deficient	3.0 (1.79 – 5.10)			
Suficient	1.0			